מתוך medicontext.co.il
By Steven Reinberg
LONDON (Reuters Health) – Progesterone and progestogens appear to be no better than placebo in managing premenstrual syndrome (PMS), UK researchers report in the British Medical Journal for October 6.
"We looked at all the high-quality randomised, controlled trials in the treatment of premenstrual syndrome symptoms with progesterone and progestogens, and found that there is no evidence to support their use as an effective treatment," co-author Dr. Paul Dimmock told Reuters Health.
Dr. Dimmock and colleagues from Keele University and North Staffordshire Hospital, Stoke-on-Trent, performed a meta-analysis of 10 randomised studies of progesterone treatment that included 531 women, and four randomised trials of progestogen treatment that included 378 women.
Analysis of all trial data combined revealed no clinically significant difference between progesterone and placebo, with an odds ratio of 1.05 favoring progesterone. For progestogens, there was a small difference in symptom relief that favored progestogens (odds ratio 1.07).
However, pooled data from all of the trials remained statistically homogeneous (p = 0.999), the researchers found.
These findings indicate there is really no progesterone deficiency in women with PMS, so these treatments do not help PMS patients, Dr. Dimmock said.
"We have done some work in Britain on prescription rates and found, to our surprise, that progesterone and progestogens are still widely prescribed. There is no rationale for prescribing these to PMS sufferers because they simply won't alleviate the symptoms of PMS," he added.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!